CREDENCE

CREDENCE : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

• This study was terminated early for efficacy. CV events and the risk of kidney failure were lower in the canagliflozin group, compared to placebo.
• There was no significant difference in rates of amputations or fractures. The results of this study differ significantly from postmarketing surveillance data for canagliflozin (i.e. reported higher rates of amputations)

Infographic

Reference

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306.

>